ALEC

Alector keeps a "Hold" rating while shifting focus to its ABC platform and a partnership with Roche that extends cash flow to 2029. The company is navigating trial setbacks by leaning on this new strategy.

Alector shares jumped about 13% in premarket trading after announcing a $75 million stock offering priced higher than the previous close. The move reflects investor interest in the company’s new capital raise.

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2026 (GLOBE NEWSWIRE) -- Alector, Inc. (“Alector,” Nasdaq: ALEC), a biotechnology company focused on developing therapies to counteract the devastating progression of neurodegeneration, today announced the pricing of an underwritten offering of common stock. Alector is selling 36,600,000 shares of common stock.

Alector’s internal fair value estimate rose from $3.10 to $3.90 per share, placing it in the lower half of analyst targets. The change reflects differing views on the Genentech AL050 deal and the broader Brain Carrier platform.

Alector released a slide deck outlining strategic advances in next‑generation neurodegeneration therapies and pipeline developments.

Analysts raised targets for several stocks, including Alector, while adjusting other companies’ forecasts.

HC Wainwright & Co. upgraded Alector to a Buy and increased its price target from $5 to $8.

Alector (NASDAQ:ALEC) outlined its strategy to advance brain-penetrant therapies for neurodegenerative diseases, highlighting an anti-amyloid beta antibody for Alzheimer’s disease and two siRNA programs targeting tau and alpha-synuclein. Chief Executive Officer and co-founder Arnon Rosenthal said t